What is VIVUS?
VIVUS is a focused organization dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. The company develops high-potential molecules with compelling safety and efficacy profiles, transforming them into proprietary products that significantly advance patient care and outcomes. VIVUS aims to improve patient quality of life, provide healthcare providers with new treatment options, foster a collaborative employee environment, and create shareholder value.
How much funding has VIVUS raised?
VIVUS has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in VIVUS
PPP
Public-Private Partnership
What's next for VIVUS?
The recent major strategic investment signals a pivotal phase for VIVUS, likely enabling the acceleration of its clinical development pipeline and commercialization efforts. This infusion of capital is expected to support the advancement of its proprietary products, further solidifying its market position in addressing unmet medical needs. The company's focus on high-potential molecules suggests a strategic direction towards expanding its portfolio and enhancing patient outcomes.
See full VIVUS company page
